CompletedPhase 1NCT00005988
Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy
Studying Acute myeloid leukaemia with myelodysplasia-related features
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dana-Farber Cancer Institute
- Principal Investigator
- Eva Guinan, MDDana-Farber Cancer Institute
- Intervention
- cyclophosphamide(drug)
- Enrollment
- 5 enrolled
- Eligibility
- 40 years · All sexes
- Timeline
- 2000 – 2002
Study locations (2)
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00005988 on ClinicalTrials.govOther trials for Acute myeloid leukaemia with myelodysplasia-related features
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT04802161Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related ChangesNational Cancer Institute (NCI)
- RECRUITINGNCT01210274Characterization of the Mechanisms of Resistance to AzacitidineCentre Hospitalier Universitaire de Nice
See all trials for Acute myeloid leukaemia with myelodysplasia-related features →